Calendario›CTMX›CX-072
CX-072
PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas
Ensayo de CytomX Therapeutics, Inc. en Tumor solido · Linfoma.
Más ensayos de: Tumor sólido · Linfoma.
- Fase
- Fase 1/2
- Estado
- Interrumpido
- Participantes
- 196
- Centros
- 31
- Fin del objetivo primario
- oct 2020
Qué significa cada fase y cada estado.
Estudio de intervención, no aleatorizado, abierto. Comenzó en ene 2017.
Este ensayo se detuvo. Motivo declarado por el promotor (del registro, en inglés): «Sponsor's decision».
Qué mide
The Number of Subjects Experiencing a Dose Limiting Toxicity (DLT) at Various Dose Levels When Given Multiple Doses of CX-072 as a Monotherapy or in Combination With Ipilimumab or Vemurafenib (28 days (dose limiting toxicity period)) (del registro, en inglés)
Cómo lo describe el promotor
En el documentoEn inglés, del registroThe purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered intravenously (IV) as a single agent or in combination with ipilimumab or vemurafenib in adult subjects with advanced or recurrent solid tumors or lymphomas. PROCLAIM-CX-072: PRObody CLinical Assessment In Man CX-072 clinical trial CX-072 is a Probody® therapeutic directed against PD-L1 (programmed cell death ligand 1). Probody therapeutics are proteolytically-activatable antibodies (Abs) designed to widen the therapeutic index by minimizing drug interaction with normal tissue while retaining anti-tumor activity. Probody therapeutics are "masked" to attenuate binding to target in healthy tissue but can become "unmasked" in the tumor microenvironment by tumor-specific protease activity. PROBODY is a U.S. registered trademark of CytomX Therapeutics, Inc.
Más ensayos de CTMX
| Ensayo | Fase | Estado | Lectura de resultados |
|---|---|---|---|
| CX-2051 | Fase 1 | Reclutando pacientes | nov 2027 (prevista) |
| CX-801 | Fase 1 | Reclutando pacientes | feb 2028 (prevista) |
| CX-904 | Fase 1 | Interrumpido | jun 2025 (real) |
| CX-2009 | Fase 2 | Completado | jun 2023 (real) |
| CX-2029 | Fase 1/2 | Completado | jun 2023 (real) |
| CX-188 | Fase 1 | Retirado antes de empezar | dic 2020 (prevista, ya pasada: sin actualizar en el registro) |
Todos los de CTMX, en su ficha.
Ficha completa en ClinicalTrials.gov (NCT03013491), actualizada en may 2025.